On this page
How do you choose the correct FDA promotional submission type?
Start from the real event: initial dissemination or publication, a voluntary request on unused drafts, required accelerated-approval presubmission, a response to FDA, or a correction or withdrawal. Establish the responsible office, audience, product, use status and original tracking reference. Those facts determine the package and correspondence; the presence of promotional material alone does not make every submission a final Form FDA 2253 report.
Before you begin
Human prescription-drug promotional submissions within the April 2022 FDA guidance scope. OPDP and APLB differ; a current supported publishing version must be verified separately.
What you will prepare: A documented submission-purpose decision, material manifest and appropriately scoped correspondence.
Sections covered in this guide (3)
Classify the real submission event
Determine whether this is postmarketing reporting at first dissemination/publication, voluntary advisory review, accelerated-approval presubmission, an agency response, correction of a missing file or withdrawal of a review request. Record the actual audience, planned or actual use date, approval state and responsible FDA office. These inputs change the package. Do not call every promotional submission “2253,” and do not assume submitting material means FDA approved it.
Build a manifest before writing correspondence
List each material ID, version, medium, audience, product/application, intended use and label baseline. Mark clean and annotated variants as related artifacts rather than different advertising concepts. Explain interactive paths, audio/video components and pieces that require physical manipulation so the reviewer can understand the actual presentation. If the use state is unknown, resolve it with the business owner before describing the package as a request for comments on unused material.
Use general correspondence only for the right task
The guidance’s IV.E includes matters such as changes in promotional contact, notice of a promotional error, certain safety updates and responses to advice where no revised materials or further advisory review are requested. State the event, affected product/materials, prior tracking reference, known facts and requested action. Do not route a complaint, warning-letter response or missing-material amendment into general correspondence simply because it is written as a letter. Standard 2253 reporting has different correspondence instructions; do not add a generic cover letter to every package.
Fictional example: the same piece, a different purpose
A brochure awaiting first use may be suitable for a voluntary advisory request. If it has already been disseminated, that fact changes the review context and must be disclosed; it cannot be described as unused to obtain a preferred review route. If the only event is a new regulatory contact, identify that administrative change without pretending the material itself is being revised.
Classify the event before selecting forms and files
Use the following decision record with the actual product and campaign facts. It summarizes the April 2022 guidance's task distinctions; it is not a substitute for current product-specific conditions or supported technical specifications.
| Actual event | Preparation route | Critical distinction |
|---|---|---|
| Initial use of final promotional material | Final 2253 reporting | Form, actual final material and current labeling; submission is not approval |
| Unused draft submitted voluntarily for input | Advisory comments | Verify use of the piece and substantially similar claims or presentations |
| Promotion subject to accelerated-approval conditions | Required presubmission | Read actual conditions and separate launch from non-launch timing |
| Material revised after agency comments | Resubmission for further review, where appropriate | Explain comment dispositions and the actual revised draft |
| Entire piece missing or rejected | Correction assessment | Original purpose and eCTD versus non-eCTD format affect handling |
| Annotated support missing while the clean piece was present | Reference-document correspondence | Do not use references to stand in for an entirely omitted piece |
| Agency letter or inquiry | Matching response category | Answer the actual communication and preserve its tracking identity |
| Review no longer wanted or material no longer intended for use | Withdrawal assessment | Voluntary review and required presubmission have different implications |
Resolve the audience from the actual intended user. Section III recommends separating health-care-professional and consumer materials. A website with distinct sections for each should be divided into separate submissions. For a mixed site without distinct sections that is not intended solely for professionals, the guidance describes submitting the entire website as consumer-directed. Do not choose an audience from the company's preferred reviewer assignment.
Keep submission purposes separate. A single launch campaign can need an advisory request at one stage and final reporting at another; those events do not belong in one undifferentiated package. Form handling also differs by office: the guidance uses Form FDA 2253 for final reporting, does not use it for OPDP draft advisory submissions, and describes draft-form handling for APLB. Consult the current form for a field-level task rather than carrying old form screenshots into a new package.
Fictional routing exercise: a campaign has an unused professional brochure, a consumer webpage already published and a missing video from an earlier eCTD 2253 submission. The shared campaign name does not make them one advisory request. Establish the brochure's eligibility, address the webpage's actual reporting facts and correct the missing video through the relevant original-submission workflow. Do not alter the publication date to make the consumer material appear unused.
Use advisory preparation, accelerated presubmission, correction and withdrawal and agency-response preparation for the next drafting step. The internal decision record should name the evidence and owner for unresolved facts; an unknown use date or review basis should remain unresolved until established.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is every promotional submission a Form FDA 2253 submission?
No. Final postmarketing reporting, voluntary advisory review, accelerated-approval presubmission and correspondence are different tasks. Form handling also differs between OPDP and APLB for drafts. Establish the actual office, purpose and material state before selecting a form or reusing an earlier submission package.
Can professional and consumer campaign materials be bundled solely because they share a campaign?
The guidance recommends separate submissions by audience. For websites, assess whether there are distinct professional and consumer sections and apply the relevant audience instructions. A campaign name or common creative concept does not remove those distinctions or establish the appropriate submission purpose.
What if nobody can establish whether the material was already used?
Treat dissemination status as an unresolved input. Check publication, distribution and campaign records with the responsible owners before representing the piece as unused. The voluntary process is intended for pre-use input, and a new filename or redesigned layout does not prove that substantially similar claims were never disseminated.
Does FDA technical acceptance mean the promotional material was approved?
No. Technical receipt, advisory comments, a substantive regulatory decision and the company’s dissemination decision are different events. Record what actually occurred and what remains unresolved. A successful transmission does not establish that claims, risk presentation or the chosen reporting route are appropriate.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA: Submissions of Promotional Labeling and Advertising ↗April 2022 final, Revision 1; IV.A–J, VI.E–H and VII. PDF production/PRA update April 2023 does not change the cover revision. Its legacy backbone syntax is not an eCTD v4 implementation guide. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.15. A heading identifies placement, not mandatory applicability.